SOURCE: Bonaventura Reproductive Medicine and Repromedix

May 07, 2008 11:33 ET

Bonaventura Reproductive Medicine to Offer Pioneering Test of a Woman's Biological Clock

PlanAhead™ Test Offers Most Accurate Measurement of a Woman's Biological Clock

CARMEL, IN--(Marketwire - May 7, 2008) - Bonaventura Reproductive Medicine today announced it will offer the Repromedix's PlanAhead test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs, which inevitably declines as a woman ages and her "biological clock ticks." PlanAhead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.

"Bonaventura Reproductive Medicine has been a pioneer of cutting edge assisted reproductive technologies," said Leo M. Bonaventura, MD, founder/Medical Director of Bonaventura Reproductive Medicine. "Our mission is to provide our patients with the most advanced testing and treatment options, and the PlanAhead test will provide women with the individual assessment of their own ovarian reserve to help them make more informed decisions about when to have a child. We're pleased to be the first in Indiana to offers this critical new test."

"The PlanAhead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The PlanAhead test offers similar information to the general public via a simple blood test."

Repromedix Corp., the PlanAhead test co-developer and leading national diagnostic laboratory for fertility testing, selected Bonaventura Reproductive Medicine to be one of a select number of IVF centers to debut the test. Repromedix will expand the PlanAhead test launch to major markets across the United States throughout 2008.

PlanAhead is now available to women in the greater Indiana area, and women interested in the PlanAhead test can purchase a test online at www.planaheadtest.com/us or at Bonaventura Reproductive Medicine, where they can also have their blood drawn. The blood sample is sent to Repromedix, whose lab performs the advanced testing and submits the report and recommendations to the patient's physician. The cost of the PlanAhead test is $350.

Women interested in learning more about PlanAhead, should visit: www.planaheadtest.com.

About Bonaventura Reproductive Medicine (www.bonaventurafertility.com)

Over the past 30 years, Bonaventura Reproductive Medicine has distinguished itself from other infertility practices by emphasizing that each patient is an individual. We use a personal approach to our patients by integrating the most advanced procedures available with our patients' unique chemistry and lifestyle. We understand the stress and frustration associated with infertility, and we have compiled resources to help limit the impact impaired fertility has on our patients' lives.

About Repromedix (www.repromedix.com)

Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.

Contact Information